Olympus Sets Sights on Growth in Its Refocused Medical Business
Olympus Corporation (“Olympus” – Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its medical business with the aim of achieving further growth and profitability by elevating the standard of care in targeted disease states. The medtech leader’s approach involves greater focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases that will increasingly impact the global population, as well as more focused investment in next-generation technologies that will enhance patient care pathways.
Three major principles guide the company’s approach:
- Focus the portfolio on disease states where Olympus can maximize impact
Olympus will focus on the disease states where it can maximize its positive impact, including those targeted by its Gastrointestinal, Urology, and Respiratory business areas. Aging populations worldwide face increasing levels of chronic disease that present unmet needs matching Olympus’ competitive strengths, as well as opportunities to continue providing solutions for colorectal cancer, benign prostatic hyperplasia, urological stone disease, urinary disease, and lung cancer. Other medical areas will remain important business components and support Olympus’ goal of striving for greater profitability, contributing to the company-wide goal of at least 5-6% annual growth and an operating profit margin of 20% or higher.
- Shape the future by investing in new ways to enhance the standard of care
Olympus will concentrate on a care pathway oriented approach, procedural optimization, and next-generation solutions development. The company’s innovation pipeline includes plans to optimize its endoscope line through complementary single-use scopes; integrate computer-assisted diagnosis, cloud, and endoscopy workflow management technologies; and explore endoluminal therapy breakthroughs.
- Enable Olympus to compete even more effectively on a global scale
The company’s approach includes enabling factors, such as an expanded global R&D network, stronger Medical and Scientific Affairs, and a more centralized Quality Assurance and Regulatory Affairs function. Merger and acquisition momentum is expected to stay strong via the Olympus business development function, which drove significant acquisitions over the past 2 years. Additionally, the new Olympus wholly owned corporate venture capital fund will prioritize early-stage investments and aim to stimulate next-generation innovations.
Olympus’ new direction comes on the back of strong half-year figures, including a record operating profit margin of 18.5% and strong year-on-year growth of 31%, as announced on November 5. Medical business revenue is expected to reach a record high for fiscal year 2022. Olympus also reiterated its goal of operating with a 20%-plus profit margin and a midterm annual growth rate of 5-6% in fiscal year 2023.
Since 2019, Olympus has completed the sale of its Imaging business and announced the impending transition of its Scientific Solutions business into a newly established, wholly owned subsidiary. A package of operational changes brought about enhancements in efficiency, profitability, R&D processes, and customer care.
“We are witnessing stunning changes to the global healthcare industry due to the aging of populations, the rise of chronic diseases, integration of digital technologies, health and biotech advancements and a growing emphasis on less-invasive treatments,” said Yasuo Takeuchi, President and CEO of Olympus. “With the successful transformation of Olympus since 2019, we have become a global medtech leader. Today we have unveiled a unifying value creation direction that is designed to elevate the standard of care, optimize the treatment journey for patients and healthcare professionals, and benefit all stakeholders, while accelerating our ability to deliver on the profitability and growth targets we have set.”
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Korea Ranked 8 th in Nation by Best Workplaces™ Korea and Awarded Best Workplaces™ for Parents and Most Respected CEO22.2.2024 23:46:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products, and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, proudly announces its achievement of ranking 8th in the nation as Best Workplaces™ in Korea, along with four additional Great Place to Work® 2024 Korea awards. This recognition builds on Rimini Street’s multiple culture awards and certifications across the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222652878/en/ Rimini Street Korea Ranked 8th in Nation by Best Workplaces™ Korea and Awarded Best Workplaces™ for Parents and Most Respected CEO (Photo: Business Wire) Great Place to Work® is the global authority on workplace culture, employee experience, and leadership behaviors proven to deliver market-leading revenue, employee retention, and increased innovation. Best Workplaces™ awards are gr
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data22.2.2024 22:44:00 CET | Press release
Neuraptive Therapeutics, Inc., a pioneer in nerve repair and regeneration, is proud to announce new 24-week data from the ongoing NEUROFUSE Study for NTX-001, further solidifying the product's status following the previously announced proof of concept results based on the 12-week data in January 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222942067/en/ Evan L. Tzanis, COO and EVP Head of R&D, Neuraptive Therapeutics, Inc. (Photo: Business Wire) The latest data from the multicenter, randomized, evaluator-blinded, Phase 2a NEUROFUSE Study underscores NTX-001’s sustained safety and efficacy as an adjunct treatment for transected peripheral nerves. At the 24-week mark, NTX-001 continues to demonstrate an encouraging safety profile, with lower treatment-emergent adverse event rates than the standard of care. Regarding efficacy, NTX-001 showed a statistically significant improvement in hand function and symptomatology
Datasite Acquires Zurich-based Sherpany22.2.2024 22:00:00 CET | Press release
Datasite®, a leading SaaS platform used by enterprises globally to execute complex, strategic projects, today announced that it has acquired Sherpany®, a Zurich-based board reporting and meeting management software provider. Terms of the agreement are not being disclosed and the transaction is expected to close in Q1 2024, subject to closing conditions. “Datasite is committed to delivering products that enable professionals to execute complex, strategic projects,” said Rusty Wiley, President & Chief Executive Officer of Datasite. “The acquisition of Sherpany extends our product suite with advanced functionality that facilitates board collaboration and meeting management, further enhancing organizational productivity. We look forward to integrating these capabilities into the Datasite platform, adding significant value for our customers.” Founded in 2011 and with offices across Europe, Sherpany’s software allows professionals to increase productivity by streamlining both board and gener
Announcing Moveworks.global: Where the Future of Enterprise AI Comes to Life22.2.2024 21:00:00 CET | Press release
Moveworks, the leading AI copilot platform for the enterprise, today announced registration for its annual Moveworks.global conference is now open. The event will take place on April 23, 2024, and will be held both virtually and in-person in San Jose, CA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222535446/en/ In an era where artificial intelligence is not just an advantage but a necessity, Moveworks.global is the must-attend event for industry leaders, developers, and forward-thinkers eager to explore the transformative power of generative AI in business. This event serves as a dynamic platform for participants to engage with the brightest minds in the industry. With past speakers from world-renowned companies like OpenAI, Salesforce, Honeywell, and more, attendees will learn firsthand how best-in-class organizations are leveraging generative AI to foster unprecedented levels of business agility. From global corpora
Data Roaming Without Worries, Now in Every App : eSIM Innovator 1GLOBAL gives FinTech its Own Roaming Service22.2.2024 18:39:00 CET | Press release
The range of industries adopting 1GLOBAL’s innovative services continues to grow as more than 30 million European customers will be soon avoiding roaming charges in over 160 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240222033843/en/ Data Roaming Without Worries, Now in Every App: eSIM Innovator 1GLOBAL gives FinTech its Own Roaming Service. (Graphic: Business Wire) By fully integrating the 1GLOBAL API, global fintech Revolut now offers its customers simple, fast access to 1GLOBAL's low-cost global mobile network. Once activated by the user, an embedded SIM (eSIM) is generated for the mobile device. "Without having to leave the Revolut app, users can install an eSIM within one minute,” said Hakan Koç, Founder and CEO of 1GLOBAL. “This is why players from a wide range of industries such as travel, insurance, fintech, airlines, VIP logistics and more are all coming to us to increase the range of services they of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom